Intervention Protocol

Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infection

  1. Yun Xia1,*,
  2. Jian Ping Liu2,
  3. Christian Gluud3

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 16 FEB 2011

Assessed as up-to-date: 5 JAN 2011

DOI: 10.1002/14651858.CD009003


How to Cite

Xia Y, Liu JP, Gluud C. Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infection (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD009003. DOI: 10.1002/14651858.CD009003.

Author Information

  1. 1

    b) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, Beijing, China

  2. 2

    b) National Research Centre in Complementary and Alternative Medicine (NAFKAM), Tromsø, Norway, c) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Copenhagen, Denmark, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, Beijing, China

  3. 3

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Yun Xia, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, b) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. xiayun_xy@126.com.

Publication History

  1. Publication Status: New
  2. Published Online: 16 FEB 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefits and harms of glycyrrhizin preparations for patients with chronic HBV infection.